Search research articles
Contact Us
Filters
Showing results (21-30 of 127) with videos related to
Page
of 13
Sort By:
Diabetes, Obesity & Metabolism
|
December 15, 2020
Updated meta-analysis assessing the risk of amputation with sodium-glucose co-transporter-2 inhibitors in the hallmark cardiovascular and renal outcome trials
Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
British Journal of Clinical Pharmacology
|
May 16, 2022
Serum uric acid lowering mediated by glucagon-like peptide-1 receptor agonists: Emerging considerations
Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
International Journal of Cardiology
|
August 19, 2020
Sodium-glucose co-transporter-2 inhibitor and glucagon-like peptide-1 receptor agonist combination treatment: Promising, but shall we look at other indices?
Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Acta Diabetologica
|
January 28, 2020
Pericardial fat in type 2 diabetes: not just a biomarker, but a promising treatment target?
Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
American Heart Journal
|
April 27, 2021
Sodium-glucose co-transporter-2 inhibitors and sacubitril/valsartan combination in patients with heart failure with reduced ejection fraction; does it deserve our attention?
Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
The American Journal of Cardiology
|
August 17, 2021
Meta-Analysis Addressing the Effect of Mineralcorticoid Receptor Antagonists on the Risk for New-Onset Atrial Fibrillation
Dimitrios Patoulias, Christodoulos Papadopoulos, Maria Toumpourleka, et al.
Hepatology (Baltimore, Md.)
|
June 20, 2020
Letter to the Editor: Sodium-Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes
Dimitrios Patoulias, Alexandra Katsimardou, Christodoulos Papadopoulos, et al.
The American Journal of Cardiology
|
October 20, 2020
Meta-analysis Evaluating the Risk of Atrial Fibrillation With Newer Antidiabetics Across the Cardiovascular and Renal Outcome Trials
Dimitrios Patoulias, Maria Toumpourleka, Christodoulos Papadopoulos, et al.
Polish Archives of Internal Medicine
|
June 29, 2021
Proton pump inhibitors and the development of diabetes and its complications: a risk hidden in the shadows?
Dimitrios Patoulias, Christodoulos Papadopoulos, George Kassimis, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)
|
September 27, 2021
Do background ischemic heart disease and baseline left ventricular ejection fraction affect cardiovascular efficacy of SGLT-2 inhibitors in heart failure with reduced ejection fraction?
Dimitrios Patoulias, Christodoulos Papadopoulos, George Kassimis, et al.
Page
of 13
Search research articles
Search
Showing results (21-30 of 127) with videos related to
Sort By:
Page
of 13
Diabetes, Obesity & Metabolism
|
December 15, 2020
Updated meta-analysis assessing the risk of amputation with sodium-glucose co-transporter-2 inhibitors in the hallmark cardiovascular and renal outcome trials
Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
British Journal of Clinical Pharmacology
|
May 16, 2022
Serum uric acid lowering mediated by glucagon-like peptide-1 receptor agonists: Emerging considerations
Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
International Journal of Cardiology
|
August 19, 2020
Sodium-glucose co-transporter-2 inhibitor and glucagon-like peptide-1 receptor agonist combination treatment: Promising, but shall we look at other indices?
Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Acta Diabetologica
|
January 28, 2020
Pericardial fat in type 2 diabetes: not just a biomarker, but a promising treatment target?
Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
American Heart Journal
|
April 27, 2021
Sodium-glucose co-transporter-2 inhibitors and sacubitril/valsartan combination in patients with heart failure with reduced ejection fraction; does it deserve our attention?
Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
The American Journal of Cardiology
|
August 17, 2021
Meta-Analysis Addressing the Effect of Mineralcorticoid Receptor Antagonists on the Risk for New-Onset Atrial Fibrillation
Dimitrios Patoulias, Christodoulos Papadopoulos, Maria Toumpourleka, et al.
Hepatology (Baltimore, Md.)
|
June 20, 2020
Letter to the Editor: Sodium-Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes
Dimitrios Patoulias, Alexandra Katsimardou, Christodoulos Papadopoulos, et al.
The American Journal of Cardiology
|
October 20, 2020
Meta-analysis Evaluating the Risk of Atrial Fibrillation With Newer Antidiabetics Across the Cardiovascular and Renal Outcome Trials
Dimitrios Patoulias, Maria Toumpourleka, Christodoulos Papadopoulos, et al.
Polish Archives of Internal Medicine
|
June 29, 2021
Proton pump inhibitors and the development of diabetes and its complications: a risk hidden in the shadows?
Dimitrios Patoulias, Christodoulos Papadopoulos, George Kassimis, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)
|
September 27, 2021
Do background ischemic heart disease and baseline left ventricular ejection fraction affect cardiovascular efficacy of SGLT-2 inhibitors in heart failure with reduced ejection fraction?
Dimitrios Patoulias, Christodoulos Papadopoulos, George Kassimis, et al.
Page
of 13